Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
- Oral presentation of ASPIRO results to include new data, with up to 48-weeks of follow-up for all patients in dose Cohort 1 and up to 24-weeks in the earliest patients in dose Cohort 2 - Presentation to be featured in the plenary session "Presidential Symposium & Presentation of the Top
Toggle Summary Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy
- Platform expansion combines the delivery power of AAV with the precision tools of antisense oligonucleotides to develop best-in-class treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) - Exclusive license agreement with the Research Institute at Nationwide
Toggle Summary Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO , April 5, 2019 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards
Toggle Summary Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer
SAN FRANCISCO , April 1, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Mark A. Meltz , J.D.
Toggle Summary Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO , March 8, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards
Toggle Summary Audentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Program to Support Patients Living with Rare Diseases
SAN FRANCISCO , Feb. 28, 2019 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced its support for Rare
Toggle Summary Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update
On track to select optimal dose of AT132 for the treatment of XLMTM in the second quarter of 2019, and gain final agreement on BLA and MAA submission pathways in the third quarter of 2019 On track to submit an Investigational New Drug (IND) application for AT845 for Pompe Disease in the third
Toggle Summary Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019
SAN FRANCISCO , Feb. 21, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, will host a conference call and webcast to
Toggle Summary Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO , Feb. 20, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate
Toggle Summary Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO , Feb. 8, 2019 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards